title: Breast cancer among HIV infected individuals from the ONCOVIH study, in France: therapeutic implications.
abstract: BACKGROUND
  The cross-sectional ONCOVIH study prospectively enrolled HIV-infected adults and children with newly diagnosed malignancies in France in 2006.
  
  
  METHODS
  We report the characteristics HIV-infected patients with breast cancer from the ONCOVIH study. Standardised questionnaires included characteristics of HIV infection and malignancy. Survival was estimated using Kaplan-Meier estimates.
  
  
  RESULTS
  Overall, 21 patients with breast cancer (two men and 19 women) were included with a median age of 43.8 years, (range: 30.1-65.5). At time of tumour diagnosis, the median CD4 count was 384/mm(3) (range: 180-1039) the median duration of known seropositivity 7.7 years (range: 0-20.3); 14 patients were under combined antiretroviral therapy for a median duration of 5.7 years (range: 1.1-10.6), of whom 11 had a controlled viral load (<500 copies/mL). The median tumour size was 1.8 cm (range: 1.0-7.0). In women, 17 (89.5%) had invasive ductal carcinoma, 17 (89.5%) with HER2 negative receptors, 8 (42.1%) with ER+ expression, and 7 (36.8%) with PR+ expression. A majority of women received chemotherapy (73.7%), surgery (68.4%) and radiotherapy (57.9%). Their one-year survival rate was estimated as 77.8% (95%confidence interval (CI): 58.6-97.0%).
  
  
  CONCLUSIONS
  We discuss the risk of breast cancer in infected patients, and the importance of taking into account the different contributing factors for breast cancer in HIV-infected individuals.
authors: AP-HP, Groupe Hospitalier Pitié-Salpétrière, Département d'Oncologie Médicale du Prof. David Khayat, 47 Boulevard de l'Hôpital, Paris, France. jean-philippe.spano@psl.aphp.fr
authors: Jean-Philippe
authors: JP
authors: Spano
authors: Emilie
authors: E
authors: Lanoy
authors: Nicolas
authors: N
authors: Mounier
authors: Christine
authors: C
authors: Katlama
authors: Dominique
authors: D
authors: Costagliola
authors: Isabelle
authors: I
authors: Heard
mesh_terms: D000328:Adult; D000368:Aged; D000428:Alcohol Drinking / Q000453:epidemiology; D019380:Anti-HIV Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D001943:Breast Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000532:radiotherapy / Q000601:surgery; D018567:Breast Neoplasms, Male / Q000453:epidemiology / Q000628:therapy; D018791:CD4 Lymphocyte Count; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000453:epidemiology / Q000532:radiotherapy / Q000601:surgery; D003131:Combined Modality Therapy; D003430:Cross-Sectional Studies; D004347:Drug Interactions; D004967:Estrogens; D005260:Female; D005602:France / Q000453:epidemiology; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology*; D006801:Humans; D016867:Immunocompromised Host; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000453:epidemiology / Q000532:radiotherapy / Q000601:surgery; D011374:Progesterone; D011446:Prospective Studies; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology; D011795:Surveys and Questionnaires; D015996:Survival Rate; D047368:Tumor Burden; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D000970:Antineoplastic Agents; D004967:Estrogens; D011374:Progesterone